Phase III results for siponimod in SPMS


Preliminary results from the EXPAND trial show that siponimod significantly reduces disability progression confirmed at three and six months, according to results presented at the annual meeting of the European Committee for Treatment and Research in MS (Kappos et al. ECTRIMS 2016; abstract 250). 

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page